What is the purpose of issuing these new Senior Notes?

The filing indicates the notes are part of an underwritten offering and typically such issuances are for general corporate purposes, which can include funding ongoing operations, capital expenditures, or other strategic initiatives. Specific use of proceeds beyond general corporate purposes are not detailed in this 8-K.

How do these new notes rank in terms of seniority and security?

The Notes are general unsecured senior obligations of Medtronic, Inc. They rank equally in right of payment with all of Medtronic, Inc.'s other existing and future unsecured senior indebtedness. The Guarantees from Medtronic plc and Medtronic Global Holdings S.C.A. also rank equally with their other unsecured senior indebtedness. They rank senior to any subordinated indebtedness.

What is a 'make-whole' premium, and how does it affect investors?

A 'make-whole' premium is a provision allowing the issuer to redeem debt before its maturity date. If Medtronic chooses to redeem the notes early, they will pay the principal amount plus a premium calculated to compensate investors for the future interest payments they will lose due to the early redemption. This provides flexibility to Medtronic for refinancing but means investors may not hold the notes until the full maturity date if interest rates fall significantly.

Are these notes guaranteed by the parent company, Medtronic plc?

Yes, the Notes are fully and unconditionally guaranteed by Medtronic Public Limited Company (Medtronic plc) and Medtronic Global Holdings S.C.A.

MDT 8-K: Material Agreements

Summary

This Form 8-K filing by Medtronic plc reports on the company's entry into a material definitive agreement, specifically the issuance of $150 million in aggregate principal amount of 4.625% Senior Notes due 2045. These notes are fully and unconditionally guaranteed by Medtronic plc and Medtronic Global Holdings S.C.A., and they constitute a further issuance of existing senior notes due the same year. The proceeds from this offering are intended to support the company's operations and general corporate purposes. From an investor's perspective, this issuance signifies Medtronic's ongoing need for capital and its reliance on debt financing. The notes are senior unsecured obligations, ranking equally with other existing and future unsecured senior indebtedness of Medtronic, Inc., and are guaranteed by the parent entities, placing them in a similar risk profile to existing senior debt. The maturity date of March 15, 2045, indicates a long-term financing strategy. Investors should note the provision allowing Medtronic, Inc. to redeem the notes early at a "make-whole" premium, which offers flexibility to the company but may impact investors seeking long-term yield.

Key Highlights

1Medtronic plc, through Medtronic, Inc., issued $150 million of 4.625% Senior Notes due 2045.
2The new notes are guaranteed by Medtronic plc and Medtronic Global Holdings S.C.A.
3This issuance is a further tranche of the company's 4.625% Senior Notes due 2045.
4The notes mature on March 15, 2045, with semi-annual interest payments on March 15 and September 15.
5Medtronic, Inc. has the option to redeem the notes prior to maturity at a 'make-whole' premium.
6The notes are general unsecured senior obligations, ranking equally with existing and future senior unsecured debt.

Medtronic plc 8-K Report, Material Agreement (Mar 28, 2017)

Summary

Key Highlights

Frequently Asked Questions